Dr. David Kirsch unveiled the SU2C-SARC032 findings at ASCO 2024. SARC032 is a global, multicenter, randomized phase 2 study evaluating the safety and effectiveness of combining pembrolizumab (pembro) with standard radiation therapy (RT) and surgery for patients with stage III undifferentiated pleomorphic sarcoma (UPS) and pleomorphic/dedifferentiated liposarcoma (LPS). The results indicate that adding pembro decreases the risk of cancer recurrence by 43% two years after treatment. This remarkable achievement is the result of a collaborative effort, with SARC, as the trial sponsor, proudly working together with Dr. Kirsch, Stand Up To Cancer, Merck, and other partners on this significant clinical research.

To read the full press release, please click here.

Back to top